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Canine malignant melanoma is a highly aggressive tumor with a low survival rate, and represents 
an ideal spontaneous model for the human counterpart. Considerable progress has been recently obtained, 
but the therapeutic success in canine melanoma is still challenging. Little is known about the mechanisms 
beyond pathogenesis and melanoma development, and the molecular response to radiotherapy has never 
been explored before. A faster and deeper understanding of cancer mutational processes and developing 
mechanisms are now possible through next generation sequencing technologies, and they can now be 
applied in canine species. In this study, we matched whole exome sequencing and transcriptome 
sequencing in four dogs affected by malignant melanoma at diagnosis and at disease progression to 
identify possible genetic mechanisms associated with therapy failure. According to previous studies, a 
genetic similarity between canine malignant melanoma and its human counterpart was observed. Several 
somatic mutations were functionally related to MAPK, PI3K/AKT and p53 signaling pathways, but 
located in genes other than BRAF, RAS and KIT. At disease progression, several mutations were related 
to therapy-induced genomic effects. Natural killer cell-mediated cytotoxicity and several immune-
system-related pathways resulted activated opening a new scenario on the role of T-cell lymphocytes in 
this tumor. In conclusion, this preliminary study suggests a potential role of the immune system 











 Malignant melanoma (MM) is among the deadliest forms of cancer, and it is characterized by a 
high degree of local invasiveness and high metastatic propensity (Rolih). In dogs, MM frequently 
involves the oral cavity, followed by mucosal junctions, feet (including digits) and haired skin (Spangler). 
Regardless of the anatomical location, complete surgical resection associated with regional 
lymphadenectomy and/or radiotherapy is the preferred treatment modality. Systemic chemotherapy has 
yielded controversial and quite disappointing results. Recently, attention has been paid to the role of the 
immune system in the pathogenesis and progression of canine melanoma, resulting in the development 
of two immunotherapeutic approaches, namely a xenogeneic DNA vaccine against tyrosinase (Oncept, 
Merial), and a CSPG4-immunotargeting vaccine.1 
 Despite a significant improvement in treatment during the last years, canine MM continues to be 
a major clinical challenge. Consequently, there is a need for further research on disease etiology and 
pathogenesis, possibly leading to the identification of biomarkers and drug targets, ultimately translating 
into an improvement in early diagnosis and personalized treatments. Although incompletely outlined, the 
genetic profile of canine MM has revealed similarities with the human counterpart. The mitogen-
activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways were found frequently 
activated in dogs,2-5 conversely activating mutations in BRAF, NRAS and KIT were scarcely 
identified.4,5,6 In addition, Poorman et al.7 described amplification of MYC and KIT loci, deletion of 
CDKN2A locus and reported distinctive copy number abnormalities in canine chromosome 30 encoding 
MAPK pathway genes, such as SPRED1 and TRPM7.  
 Whole-Exome Sequencing (WES) has been extensively applied in human medicine for several 
diseases (reviewed in Retterer et al.8) and recent studies in human oral MM have identified potential 
therapeutic targetable mutations.9 In dogs, studies to identify global somatic mutations by next generation 
sequencing (NGS) were conducted only in lymphoma10 and in rare congenital11, retinal12 and 
neurodegenerative13 disorders.  
In the current study, WES was performed in dogs with treatment-naive MM at diagnosis and at 
disease progression, to highlight the genetic mechanisms beyond progression. In addition, whole-
transcriptome sequencing (RNA-seq) was performed on the same samples. The main objectives were (i) 
to characterize the mutational signature via the identification of somatic short and structural variants of 
canine MM both at diagnosis and at disease progression, (ii) to combine gene mutations with gene 
expression alterations by functional analysis and finally (iii) to compare gene expression profiles at 
diagnosis and disease progression. 
 
 
MATERIALS AND METHODS 
 
Animal recruitment and sample acquisition 
Client-owned dogs affected by MM, undergoing a complete staging work-up and receiving 
treatment were eligible for recruitment. At first presentation (T0), all dogs had to undergo a surgical 
biopsy to confirm the diagnosis (Table S1). Furthermore, all dogs had to be followed-up and undergo to 
a second surgical biopsy at disease progression (T1). Signed owner consent was always obtained before 
inclusion. 
DNA and RNA extraction, WES and RNA-seq library preparation and sequencing are described in 
Supplementary Material and Methods. 
 
RNA-Seq data analysis 
The raw 50 bp single-end sequences (Sanger/Illumina 1.9 encoding) were quality-controlled by 
FastQC v.0.11.4 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/), and the low-quality bases 
(quality scores < 20) and adaptor contamination (if present) were removed by Trimmomatic14 v.0.36 
using the parameters ‘ILLUMINACLIP:TruSeq3-SE:2:30:10 LEADING:3 SLIDINGWINDOW:4:15 
MINLEN:25’. Quality assessment by FastQC was performed again on the clean reads to ensure 
contaminant-free data. The high-quality reads were mapped to the CanFam3.1 genome assembly from 
Ensembl (ftp://ftp.ensembl.org/pub/release-90/fasta/canis_familiaris/dna/) by HISAT215 v.2.1.5. The 
uniquely-mapped reads aligned to exons were counted with HTSeq16 v.0.6.1, then tested - by the 
DESeq217 R package v.1.14.1 - for the presence of differentially expressed genes (DEGs). Genes with a 
false discovery rate (FDR) ≤ 0.1 and at least 2-fold change (Log2FC > 1 or Log2FC < -1) in their 
expression between T0 and T1 were considered DEGs. The sequencing data (FASTQ files) associated 
with this study were deposited in the GenBank’s Sequence Read Archive (SRA) under the accession ID 
SRP150063. 
When comparing T0 versus T1 samples, the enriched gene ontology (GO) terms and signaling 
pathways associated with DEGs were identified by the Gene Set Enrichment Analysis (GSEA; 
http://www.broadinstitute.org/gsea/index.jsp), using the GSEA pre-ranked option. Briefly, all Ensembl 
gene IDs were collapsed to their corresponding HUGO gene symbols, then the entire normalized 
transcriptome dataset was ranked by the logarithm transformed (base 2) FC, where the up- and down-
regulated genes were assigned positive and negative values, respectively. The pre-ranked dataset was 
analyzed (1000 permutations) against the curated canonical KEGG pathways (c2.cp.kegg.v6.1), GO 
terms (c5.all.v6.1) and Hallmarks (h.all.v6.1) catalogs, from the Molecular Signatures Database18 
(MsigDB). In the present study, all gene sets with a FDR ≤ 25% were considered, but only those with a 
FDR ≤ 10% are reported here, as they represent the most negatively or positively enriched (based on the 
normalized enrichment score; NES) gene sets in the T1 samples.  
 
Somatic mutations discovery  
For WES data processing, the paired-end reads sequence quality was first verified using the reports 
generated by FASTQC toolkit (Babraham Institute, Cambridge, UK). Trimmomatic14 v.0.36 was used to 
clip adapters and trim low-quality regions accordingly (parameter ILLUMINACLIP:TruSeq3-PE-fa:-
2:10:10:8 SLIDINGWINDOW:5:20 HEADCROP:2 MINLEN:70). The reads were aligned to the 
CanFam3.1 reference genome (Broad Institute, Cambridge, MA; released Sep. 2011; downloaded from 
Ensembl release 87) using BWA19 mem v.0.7.7. SAMtools20 v.1.8 flagstat was used to evaluate the 
number and percentage of reads that mapped on the genome. Sorting, flagging of PCR duplicates and 
read group assignment were performed by means of PICARD toolkit 
(http://broadinstitute.github.io/picard/). A local realignment, using the Genome Analysis Toolkit21 
(GATK) v.3.7 tools RealignerTargetCreator and IndelRealigner, were performed to correct any 
misalignment around small insertions and deletions (indels). Then, the GATK tools BaseRecalibrator 
and PrintReads were used for base quality score recalibration. On the resulting BAM files, single 
nucleotide variants (SNVs) and indels were identified with Mutect222 and Varscan23 v.2.4.1, described 
as the two outperforming variant callers in previous studies.24,25 Additionally, loss of heterozygosity 
(LOH) was further investigated by Varscan. The dbSNP database (version 146) was used as a source of 
known variants to localize any region needing realignment (IndelRealigner), to ignore known mismatch 
on the aligned reads (BaseRecalibrator) and to distinguish true somatic variants from false positives by 
establishing stricter logarithm of odds (LOD) score threshold for the normal samples (Mutect2). Then, 
variants identified by Mutect2 and Varscan to be somatic rather than germline were selected. To obtain 
high-confidence calls, default hard filters made by Mutect2 were applied and only variants flagged as 
“pass” were retained. Conversely, for Varscan the option --tumor-purity equal to 0.90 for tumor samples 
was added, and SNVs, indels and somatic loss of heterozygosity (LOH) with a p-value  0.05 were 
selected. Finally, filtered SNVs and indels were annotated with ANNOVAR26 and Variant Effect 
Predictor27 (VEP). LOHs were annotated with Homer.28 For each sample, SNVs, indels and LOH loci 
were considered as the union of Mutect2 and Varscan filtered somatic mutations. For further analysis, 
only those SNVs and indels that were shared by a minimum of two dogs were employed. In order to 
assess the impact of tumorigenic mutations on gene expression, mRNA levels of genes harboring somatic 
SNVs were retrieved. A customized perl script was then applied to extract the read coverage of each 
allelic variant (i.e. reference and alternate allele), only genes with a minimum total coverage of 15 were 
investigated. Raw Illumina reads were deposited in the GenBank’s SRA repository under the accession 
ID SRP151732. 
 
Copy Number Aberration analysis 
For each sample, WES data were analyzed by NEXUS Copy Number v9.0 software (Biodiscovery Inc., 
CA, USA) to investigate genomic copy number variation. Copy number aberrations (CNAs) were 
identified starting from dedupped BAM files with a matched approach (“BAM ngCGH-matched”). Then, 
a FASST2 segmentation algorithm with a significance threshold of 5.5e-06 was applied. Aberrations 
were defined as a minimum of 3 consecutive segments with log2 tumor/reference ratio value of >1.0 
(high gain), 1.0 to 0.2 (gain), −0.25 to −1.5 (loss), <−1.5 (big loss). Recurrent CNAs across multiple 
samples were determined within NEXUS using an involvement threshold of 50%. Statistical significance 
was then determined using the GISTIC algorithm with a G-score cut off of G > 1.0 and a significance of 
Q < 0.05. Copy number aberration frequency comparisons amongst T0 and T1 were performed in 
NEXUS using Fisher’s exact test with differential threshold of > 50 % and significance p-value < 0.05. 
 
Functional analysis 
To call variants that differ between T0 and T1, Varscan was used with the somatic functionality. Variants 
were annotated with ANNOVAR and for intergenic locations only variants within 5 kb distance were 
retained. Then, to extract biological information by the identification of significant gene ontologies and 
KEGG pathways, variants were collapsed to genes and mutated genes (MGs) were analyzed by the 
Cytoscape plugin ClueGO.29 In this study, a right-side hypergeometric test was used for the p-value 
calculation, followed by the Benjamini-Hochberg adjustment for multiple test correction.30 A 
pathway/ontology with a FDR <0.05 was considered significant. Based on the kappa score threshold 
(≥0.4), the significant pathways/ontologies were functionally clustered into groups and displayed in a 
network, in which a node represented a biological function, and an edge between the nodes indicated that 





Clinico-Pathological features  
Four dogs were enrolled: 1 mixed breed, 1 Golden retriever, 1 Labrador retriever and 1 English setter. 
There were 3 intact males and 1 spayed female. Age ranged between 8 and 13 years, and weight ranged 
between 20 and 38 kg. Three dogs had an oral MM, and 1 dog had a nail bed MM. Three MMs were 
staged T2N0M0, and 1 T3N1M0. All dogs were irradiated with 5 bi-weekly fractions of 6 Gy each, up 
to a total dose of 30 Gy; 3 dogs received adjuvant chemotherapy and 1 dog was treated with 
immunotherapy. At the time of disease progression, the tumor was biopsied again in all dogs, after 139, 
175, 204, and 231 days, respectively, from diagnosis. At the end of the study, all dogs had died because 
of local progression (n=2) after 139 and 270 days, respectively, or distant metastasis to skin (n=1) after 
188 days, or lungs and liver (n=1) after 221 days from diagnosis. 
 
Gene expression profiling reveals immune signatures differentiating MMs at first presentation versus 
disease progression  
Four pairs of matched melanomas obtained from dogs at T0 and T1 were analyzed by RNA-Seq. 
A summary of the sequencing output, quality scores, and mapping percentage is reported in Table S2. 
Comparing the transcriptomes of T1 and T0 samples (T1 vs T0), a total of 25 and 29 protein-coding 
genes were found differently regulated in the biological and technical replicates, respectively (Table S3). 
To define a list of non-biased DEGs, only those genes that overlapped (n=18) between the two 
independent analyses (biological and technical replicates) were considered as the final DEGs list (Table 
S3). Of the 18 DEGs, 15 genes were downregulated at T1, with ASPRV1, MSTN and SPINK7 being the 
most downregulated genes, while the other 3 genes were upregulated (Table S3). Interestingly, by GSEA, 
immune system-related pathways were mainly enriched in T1, including genes associated with natural 
killer cell mediated cytotoxicity, chemokines and T-cell receptors. A complete list of all enriched GO 
terms, KEGG pathways, Cancer Hallmarks and the relative enrichment plots are reported in Table S4, 
Figure S1, Figure S2 and Figure S3. 
 
CNA analysis identifies a similar pattern of chromosomal aberrations in MMs at first presentation 
and disease progression  
The CNA analysis showed both focal and broad chromosomal aberrations in all MMs, totaling from 10 
Mb to 100 Mb and affecting hundreds of genes (Figure 1). Noteworthy, amplifications prevailed over 
deletions. The extension and the number of CNAs was increased in T1 compared to T0. However, the 
comparison of CNA frequency by GISTIC revealed no significant regions distinguishing firstly-
occurring and progressed tumors. Analyzing T0 and T1 separately, no regions reached the threshold for 
recurrent CNAs calling. Conversely, exploring all the MMs together, recurrent gains were found on 
Canis Familiaris autosome (CFA) 10, 27, 30 and 38 (G>4.8 and Q<1.945e-02), whereas CFA 2, 11, 30, 
31 and 38 presented recurrent losses (G>2.4 and Q<3.877e-02) (Table S5). The most frequent copy 
number gains were located on CFA 6, 8, 9, 17 and 25 (Table S6) and occurred in all tumors. The most 
recurrent copy number loss (50% samples at T0, and 75% at T1) involved CFA 11 and was a ~600kb 
region located at 41,055,923-41,652,538 (Table S6) encompassing CDKN2A locus. A focal amplification 
located on CFA 10 and corresponding to MDM2 locus (50% samples at T0 and 50% at T1) was also 
identified. Interestingly, 2 out of 4 dogs showed a characteristic aberration on CFA 30 displaying a 
sigmoidal pattern of copy number loss (spanning 0.5-12 Mb) followed by a gain (spanning 9.5-19 Mb). 
In this articulated region, the amplification contained 12 gene loci, including SLC27A2, GABPB1, USP8, 
TRPM7, SPPL2A and CYP19A1, whereas SPRED1 and FAM98B were located within the region of copy 
number loss. 
 
WES shows an additional burden of mutations in MMs at disease progression 
At T0, a total of 6,807 somatic mutations were found: 4,036 SNVs, 971 indels and 1,800 LOH calls, 
respectively (Table S7). However, only 1 non-synonymous SNV, four non-coding SNVs and 1 frameshift 
substitution were in common in at least 3 tumors and none when considering all T0 samples (Figure 2A 
and 2C). The median tumor mutational burden (TMB) was 4.01 coding mutations/Mb (range 3.37-5.63). 
At T1, 8,246 somatic mutations were identified: 4,866 SNVs, 1,094 indels and 2,286 LOH calls, 
respectively. Two non-coding SNVs were shared by all tumors, while 5 non-coding SNVs and 1 LOH 
call were in common in 3 dogs (Figure 2B and 2D) The median TMB was 5.1 coding mutations/Mb 
(range 4.6-6.16). 
A total of 8,902 SNVs were identified at T0 and T1, and the ratio of transitions (5,779) to transversions 
(3,123) was 1.85. Also, a significant higher rate of C>T/G>A transitions (Fisher’s test, p<0.01) was 
calculated (Table S8 and Figure 3). Using signatures of mutational processes published by Alexandrov31 
in 2011, MMs revealed a prevalence of signature 1B, 7 and 11, resembling human head and neck cancers 
and melanoma. 
A total of 101 and 109 somatic mutations (SNVs and indels), which were shared by at least 2 dogs, were 
observed at T0 and at T1, respectively (Table S9). By comparing the somatic mutations in each dog at 
diagnosis and disease progression, on average the 15.5% (10.3%-23.6%) was found in common, the 
20.7% (15%-27.6%) of which was exonic with predicted protein sequence effects (Table S10). Overall, 
most of the somatic mutations were identified in intronic and intergenic regions. A total of 17 (17%) and 
18 (16.5%) somatic mutations were identified in the exons at T0 and T1, respectively. Distribution and 
consequences of coding mutations according to ANNOVAR and VEP are depicted in Figure 3. 
Interestingly, 15 somatic mutations were in common across all samples including genes such as 
TMEM256-PLSCR3, DCAF10, LAMA3, GALC, SMARCAL1, TSPYL1, SOX17, MCM5, and CYP2A13. 
The frame shift substitutions harbored on TMEM256-PLSCR3 (chr5:32330460:A>-C) and on SOX17 
(chr29:5979449:G>-TT) and the non-silent SNV on GALC (chr8:59317742:A>C) were the sole coding 
mutations. A total of 94 mutations were found in at least 50% of T1 samples and never detected at T0. 
Exonic mutations were 7 non-silent SNVs, 1 non-frameshift substitution and 1 non-frameshift deletion. 
Notably, the non-frameshift deletion was located on TRPM1 (chr3:37948404:CCC>-) and one of the 
non-silent SNV on gene eEF1A1 (chr3:60899961:G>A). 
When integrating somatic mutations with gene expression data, an average of 70% of mutations was 
expressed. Only 11 and 9 somatic mutations were supported by RNA-seq reads in at least 2 dogs at T0 
and T1, respectively. When comparing expressed mutations between T0 and T1, only a small number 
was in common (26.5%). Genes belonging to keratin family and keratin associated proteins (KRTAP) 
were considered to be related to the sampling site, rather than being associated to the disease itself.32 The 
coding mutation located on GALC gene was covered by RNA-seq reads in 6 MMs. 
To investigate the presence of RNA-seq reads that supported genes with somatic mutations, SNVs and 
indels were collapsed to genes. Particularly attractive were genes including AHNAK, being mutated in 6 
out of 8 samples, LINS1 and UBA1 at T1, and PRKCDBP at T0. A functional analysis was also performed 
using Varscan and a total of 2,471 variants were identified differentiating MMs at T0 and T1. When 
variants were collapsed to genes, a total of 12 genes were shared among all dogs. Using ClueGO with 
the MGs in common in at least 2 samples (n=171), pathways related to drug and hormone metabolism 
were significantly overrepresented (Table S11 and Figure S4). However, considering the low number of 






Understanding the relationship between therapeutic treatments and the dynamics of mutations in 
naïve and progressed tumors has dramatically changed the therapeutic perspectives in many human 
cancers. Overall and event free survival in dogs with MM are relatively short, and the molecular 
mechanisms beyond tumor progression have never been investigated. In this study, we used WES, 
incorporating a comprehensive analysis of copy number, SNVs, and mutational signatures, from 
prospectively collected canine MM to compare primary tumors with matched samples at disease 
progression after radiotherapy. Furthermore, we performed RNA-seq on the same samples to evaluate 
the phenotypical impact of variants and to identify mutated alleles that are then RNA transcribed. 
When considering mutational profiles, treatment-naïve melanomas showed similar signatures to 
human melanoma and TMB also reflected the high complexity;33,34 furthermore, a significant higher rate 
of C>T/G>A transitions was found. At progression, the signatures remained unchanged, whereas TMB 
was increased. By definition, TMB measures the number of mutations carried by tumor cells. Even if 
increased, TMB may be associated in primary instance to tumor clonal evolution after treatment due to 
selective pressure. Recent studies have reported that tumors with a higher number of mutations have a 
higher likelihood to respond to immunotherapy, but this is still unexplored in dogs. 
Due to the low number of cases in our series, GISTIC algorithm didn’t identify chromosomal 
aberrations being able to differentiate MM at first presentation and at progression. However, interesting 
data were obtained when comparing specific aberrations between matched tumors. In two dogs, a 
peculiar sigmoidal pattern aberration on CFA 30, that was previously described by Poorman et al.7 in 
canine oral MM, was observed in treatment-naïve melanomas and retained at progression. The 
amplification comprises important genes, such as SLC27A2, GABPB1, USP8, TRPM7 and SPPL2A. In 
the same genomic region, loss of SPRED1 was also found. The deletion of SPRED1 and the amplification 
of TRPM7 have been demonstrated to cause activation of MAPK signaling pathway.4,7 Examining RNA-
seq data, TRPM7 expression was increased up to 20 times in tumors presenting the amplification than in 
MM showing no aberration. Similarly to other canine tumors, loss in CDKN2A locus was observed in 
two dogs both at T0 and T1, and one dog acquired the deletion at disease progression.7,35 In human 
mucosal melanoma, the CDKN2A locus is a commonly deleted region, and inactivation leads to 
unregulated cell proliferation36. A recurrent focal amplification on MDM2 locus was identified, 
underlining an additional interaction with p53 signaling pathway. Moreover, tumors with amplification 
showed up to 19 times higher than MM with no aberrations. MDM2 is a p53 negative regulator promoting 
tumor formation by targeting several tumor suppressor proteins.37 This gene itself is transcriptionally-
regulated by p53, but overexpression due to amplification was reported in a variety of different human 
cancers, including melanomas, but never reported in dogs before.37 
Unexpectedly, when comparing mutations at T0 and T1, only a small fraction was in common; 
furthermore only 20% of these mutations were exonic with predicted protein sequence effects. However, 
this reflects a global result that was obtained from WES analysis. Indeed, the majority of mutations were 
identified in the intronic and intergenic regions, revealing a significant percentage of off-target sequences 
in the canine exome enrichment protocol.38 This result also explains the observed 
transitions/transversions ratio (2.0) that is generally associated to SNVs located in regions other than 
exome.39 Finally, a more pronounced selective pressure in the exonic regions of the tumor might also 
explain a higher variation in noncoding regions.40 
 Among the genes affected by exonic mutations both at T0 and T1, GALC showed a non-silent 
SNV that was confirmed by the absence of reads in RNA-seq. GALC encodes a lysosomal protein, which 
hydrolyzes glycosphingolipids leading to the consequent production of bioactive lipids that negatively 
affect cancer progression.41,42 Also, Sox17 harbored at the genomic level a frameshift mutation that was 
not supported by RNA-seq reads. This transcription factor is considered an antagonist to canonical Wnt/β 
catenin signaling in several malignant tumors, and its down-regulation is associated with progression in 
both primary and metastatic human melanomas.43 Conversely, target melanoma oncogenes, such as 
BRAF, RAS and KIT, did not harbor variants, thereby confirming previous findings.4-6 
When exploring genes harboring mutations only in T1, a non-frameshift deletion located on 
TRPM1 was identified. The number of reads mapping TRPM1 was reduced compared to dogs not 
harboring this mutation. TRPM1 gene encodes for a calcium permeable cation channel involved in 
regulation of melanocyte physiology and melanoma development.44 Loss of TRPM1 expression has been 
correlated to melanoma aggressiveness45 and is now considered an independent prognostic marker of 
disease free and overall survival in human MM.46,47 Our results showed a relationship between TRPM1 
non-frameshift mutation and gene expression but no association with event free or overall survival was 
obtained, possibly due to the low number of samples. However, no radiotherapy effects are documented 
for TRPM1 molecular changes. A non-silent SNV was located on eEF1A1 and further characterized by 
absence of reads on variant allele. eEF1A1 has been proposed as a premature senescence marker48 and 
its expression was found to be decreased after radiotherapy both in vitro and in vivo, suggesting that 
premature senescence represents a significative pathway in radiation-induced tumor regression.49 
Mutations on eEF1A1 might be one of the causative mechanisms by which radiotherapy induces cellular 
senescence contributing to tumor response.  
We next investigated RNA-seq data to compare transcriptome of naïve melanomas with matched 
samples at progression. A positive enrichment of several immune-system-related pathways, such as 
natural killer cell-mediated cytotoxicity, was found in progressed MM. Melanoma is an immunogenic 
tumor and its relationship with the host immune system is currently under investigation50. Different 
studies have shown the capacity of melanoma to activate or modulate the adaptive immune response, 
resulting in a balance between survival and proliferation of tumor cells.50,51 Interestingly, tumors that 
progressed after radiotherapy were able to selectively modulate the immune system in their favor. Our 
data opens a new perspective on the role of this lymphocytes subset in canine MM after radiotherapy.50,52 
In MMs at progression, a negative enrichment of several fatty acid metabolism pathways was also 
identified. Even if never described in dogs, this data is not surprising considering the ability of cancer 
cells to reprogram their metabolic pathways and microenvironment to satisfy both proliferation and 
survival demands.53-55 This ability should be considered in future targeted therapies. 
In conclusion, the preliminary results from our study confirm the genetic similarity of canine MM 
with its human counterpart.2,56,57 Genetic molecular mechanisms also seem to be more related to copy 
number aberrations rather than point mutations. Notably, somatic mutations are located in genes other 
than BRAF, RAS and KIT, nevertheless modulating the same signaling pathways, such as MAPK, 
PI3K/AKT and p53 signaling pathways. We identified several allelic mutations related to therapy-
induced genomic effects. A larger number of cases and functional studies will help to identify their 
biological functions in future studies. Finally, on one side, transcriptomic pathway analysis has revealed 
the importance of adaptive immune system regulation and on the other side the increased of TMB in 
disease progression showed a higher likelihood to respond to immunotherapy, opening the opportunity 
to further investigate the potential of immunotherapy in canine melanoma. 
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Figure 1. Circos plot depicting the Copy Number Aberrations (CNAs) in the eight tumor samples. 
Chromosome numbers are identified in the outer-most ring. From outer to inner circles, second and third 
circles represent CNAs in disease progression samples (T1), as heat map and scatter diagram, 
respectively. Fourth and fifth circles represent CNAs in naive samples (T0), as heat map and scatter 
diagram, respectively. Blue dots correspond to amplifications (>0.25) while red dots correspond to 
deletions (<-0.25). The dimension of the dots increase with the size of the amplification/deletion. 
Figure 2. Venn’s diagrams of somatic variants across samples. Illustrative representation of single 
nucleotide variants (SNVs) and indels at T0 (A) and at T1 (B) melanomas and LOH calls across the T0 
(C) and T1 (D) samples.  
Figure 3. Illustration of ratio frequencies of transitions and transversions at presentation and 
disease progression. Naïve and progressed melanomas showed similar pattern of mutations, with a 
significant prevalence of C>T/G>A transitions. 
Figure 4. Coding somatic mutations (SNVs and indels) distribution and consequences across the 
eight tumor samples. Genomic distribution of somatic mutations (A). Number and consequences of 
coding somatic mutations (B). Number and consequences of coding somatic SNVs (C). 
 
 
SUPPORTING INFORMATION DESCRIPTION 
 
Supplementary Materials and Methods. Detailed description of DNA/RNA isolation and WES/RNA-
seq library preparation and sequencing. 
Table S1. Clinical data of dogs included in the study. 
Table S2. RNA-seq sequencing yields, quality scores, and reads mapping summary. 
Table S3. Differentially expressed genes (DEGs) at disease progression- compared with naïve- 
canine melanomas (T1 vs T0), in both the biological and technical data sets. Table S3 contains three 
worksheets organized as follow: S3.1. T1 vs T0 DEGs in biological replicates; S3.2. T1 vs T0 DEGs in 
technical replicates; S3.3. List of overlapping DEGs between biological and technical replicates. Column 
A: Dog ENSEMBL gene ID. Column B: mean count. Columns C, D: log2 fold change (FC), and standard 
error. Columns E, F: nominal and adjusted (Benjamini-Hochberg) p-value. Column G: dog gene symbol. 
Column H: gene type. Column I: gene description. 
Table S4. Gene Ontology (GO) terms, KEGG pathways and Cancer Hallmarks significantly 
enriched identified by Gene Set Enrichment Analysis in disease progression tumor samples (T1). 
Column A: enrichment direction (POS=positively enriched; NEG= negatively enriched). Column B: 
GO/KEGG/Cancer Hallmarks terms ID. Columns C, D, E: gene set size, enrichment score (ES) and 
normalized enrichment score (NES). Columns F, G, H: nominal p-value, False Discovery Rate (FDR) q-
value and familywise-error rate (FWER) p-value.  
Table S5. Recurrent Copy Number Aberrations identified in the eight samples by GISTIC algorithm 
using NEXUS software. 
Table S6. Most frequent copy number gains and losses in all eight samples. 
Table S7. Distribution of SNVs, Indels and LOH across all the tumors. 
Table S8. Ratio of transitions and transversions at presentation and disease progression. 
Table S9. List of common somatic mutations (SNVs and indels) across the T0 and T1 melanomas. 
Table S9 contains two worksheets organized as follow: S9.1. List of common somatic mutations in at 
least 2 dogs across the T0 samples; S9.2. List of common somatic mutations in at least 2 dogs across the 
T1 tumors. Columns A, B: Dog ID samples presenting the mutations and number of mutations per group 
of samples. Columns C, D: variant location on CanFam genome. Columns E, F: reference allele and 
variant allele. Column G: Dog ENSEMBL gene ID, Columns H, I, J: ANNOVAR variant annotation, 
gene symbol and gene type, Columns K, L: Variant Effect Predictor (VEP) impact and Amino Acids 
substitutions, Columns M: dbSNP variant ID, Column N: SNVs Sorting Intolerant from Tolerant (SIFT) 
effect prediction. 
Table S10. Distribution of somatic mutations (SNVs and indels): intra-individual comparison. 
Table S11. List of overrepresented pathways and GO terms identified by ClueGO using the list of 
mutated genes (T1 vs T0). 
Figure S1. Gene Set Enrichment Analysis (GSEA) enrichment plot (score curves) of the most 
‘negatively-enriched’ KEGG pathways in T1, compared with T0. Gene Set Enrichment Analysis was 
performed with the canonical pathway gene sets in GSEA Molecular Signatures Database (MSigDB). 
The green curve corresponds to the enrichment score curve, which is the running sum of the weighted 
enrichment score obtained from GSEA software. a, b, c, and d denote the most negatively enriched 
(negative NES) pathways (i.e., gene sets): Retinol metabolism, sphingolipid metabolism, arachidonic 
acid metabolism, and steroid biosynthesis pathway, respectively. NES = Normalized Enrichment Score; 
FDR = False Discovery Rate (q value). 
Figure S2. Gene Set Enrichment Analysis (GSEA) enrichment plot (score curves) of the most 
‘positively-enriched’ KEGG pathways in T1, compared with T0. Gene Set Enrichment Analysis was 
performed with the canonical pathway gene sets in GSEA Molecular Signatures Database (MSigDB). 
The green curve corresponds to the enrichment score curve, which is the running sum of the weighted 
enrichment score obtained from GSEA software. a-h denote the most positively enriched (positive NES) 
pathways (i.e., gene sets): (a) natural killer cell-mediated cytotoxicity, (b) primary immunodeficiency, 
(c) complement and coagulation cascades, (d) prion diseases, (e) B cell receptor signaling pathway, (f) 
antigen processing and presentation, (g) chemokine signaling pathway and (h) T cell receptor signaling 
pathway, respectively. NES = Normalized Enrichment Score; FDR = False Discovery Rate (q value). 
Figure S3. Gene Set Enrichment Analysis (GSEA) enrichment plot (score curves) of the top 5 
‘negatively-enriched’ biological processes (GO terms) in T1, compared with T0. Gene Set 
Enrichment Analysis was performed with the GO term gene sets in GSEA Molecular Signatures 
Database (MSigDB). The green curve corresponds to the enrichment score curve, which is the running 
sum of the weighted enrichment score obtained from GSEA software. a, b, c, d and e denote the most 
negatively enriched (negative NES) biological processes: keratinocyte differentiation, skin development, 
epidermal cell differentiation, keratinization, and epidermis development, respectively. NES = 
Normalized Enrichment Score; FDR = False Discovery Rate (q value). 
Figure S4. Functional map of the mutated genes (T1 vs T0) using ClueGO. In the network, the Gene 
Ontology (GO) biological terms and pathways were identified as nodes and linked based on their kappa 
score level (>0.4) and False Discovery Rate (FDR) < 0.05. The size node represents the term enrichment 
significance. Functionally related groups partially overlapped. The similar GO terms/KEGG pathways 
are labelled in the same color. The list of mutated genes in common in at least 2 samples was used 
(n=171). 
